MyFinsight
Home
Blog
About
Short-term investments
$293,978K
(33.15%↑ Y/Y)
Cash and cash
equivalents
$38,626K
(-26.19%↓ Y/Y)
Prepaid expenses and
other current assets
$7,396K
(-22.43%↓ Y/Y)
Total current assets
$340,000K
(20.29%↑ Y/Y)
Long-term investments
$90,986K
(208.32%↑ Y/Y)
Property and equipment,
net
$67,382K
(-14.55%↓ Y/Y)
Operating lease
right-of-use asset
$37,739K
(-10.07%↓ Y/Y)
Restricted cash
$10,292K
(0.00%↑ Y/Y)
Other long-term
assets
$3,692K
(-3.55%↓ Y/Y)
Total assets
$550,091K
(16.89%↑ Y/Y)
Total liabilities and
stockholders equity
$550,091K
(16.89%↑ Y/Y)
Total stockholders
equity
$436,175K
(26.59%↑ Y/Y)
Total liabilities
$113,916K
(-9.61%↓ Y/Y)
Accumulated deficit
-$2,095,993K
(-8.57%↓ Y/Y)
Accumulated other
comprehensive income (loss)
-$518K
(-1051.11%↓ Y/Y)
Additional paid-in capital
$2,532,341K
(11.32%↑ Y/Y)
Lease liability,
noncurrent
$70,353K
(-11.22%↓ Y/Y)
Total current
liabilities
$31,727K
(0.16%↑ Y/Y)
Other long-term
liabilities
$11,836K
(-21.70%↓ Y/Y)
Common stock, 0.001 par
value 800,000,000 and...
$345K
(56.82%↑ Y/Y)
Accrued and other
current liabilities
$25,763K
(-3.96%↓ Y/Y)
Accounts payable
$5,964K
(22.94%↑ Y/Y)
Back
Back
Balance Sheet
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)
source: myfinsight.com